

Another Xenia portfolio company completes a funding round:

Medi-Tate Raises Approx. NIS 3.6 million at an NIS 32 Million Valuation

Medi-Tate offers an innovative, minimally invasive solution for benign prostate hyperplasia, a condition suffered by 20%-50% of all men from the age of 65

Over the past month, other Xenia portfolio companies have cumulatively raised approx. NIS 28 million

Israel, Herzliya, July 24, 2013, Xenia Venture Capital (TASE: XENA), hereby announces that Medi-Tate, a portfolio company (in which Xenia holds 23.95%), has concluded an additional funding round of USD 3.6 million at a NIS 32 million valuation. Medi-Tate develops products designed to treat urethral and prostate conditions, its flagship product being designed for treating patients with benign prostate hyperplasia (BPH). The company has obtained CE marking for marketing the device in Europe.

According to Xenia CEO Anat Segal: "We are happy to announce that we have concluded another funding round for a portfolio company, the third one this month. As we have mentioned in the past, most of our portfolio companies (tech and medical device companies) are reaching sales, maintain strategic agreements with leading companies and hold regulatory permits for their products. Consequently, the companies are raising great interest among entities and investors and, as previously mentioned, only this month we have raised a total of NIS 28 million for our portfolio companies."

"Medi-Tate is showing good clinical results among patients and its products are directed at a large market that spans over USD 1 billion in sales in Europe. We believe that in the coming year, the portfolio companies will begin achieving ever-increasing revenues, while creating value for Xenia's shareholders."

In the United States alone there are approx. 15 million men suffering from benign prostate hyperplasia. Only about 3 million of them are treated, 90% with medications and 10% through surgical intervention. In the United States this market is estimated at USD 3 billion, while in the rest of the world more than 500,000 procedures are carried out every year.

About Xenia Venture Capital:

Xenia Venture Capital is a publically traded investment company which operates a privatized technology incubator that invests in seed stage start ups and initiatives in the fields of medical devices and IT. Among Xenia's founders and main shareholders are the Novacom Group and C. Mer Industries, leading institutional investors such as IBI, Menora Insurance Group, Dash Apax, Mivne Taasia (of the Fishman Group), Anat Segal (CEO), as well as additional hi tech and industry figures. Xenia's Board of Directors and Advisory Board comprises highly successful entrepreneurs and high-tech industry executives, including Haim Mer, Tal Menipaz (Chairman of the Board), Prof. Gaby Barabash, Dr. Yafit Stark, Prof. Yossi Shacham, and others. The aim of the company is to jump-start and accompany start up companies in the field of technology and medical devices, striving to increase the companies' chances to succeed and realize their business potential. Since its inception, Xenia has invested in dozens of companies, many of which have completed follow-on investment rounds, launched products in global markets, reached significant sales and profitability, and formed valuable strategic partnerships.

Please visit our website at: www.xenia.co.il